MIFH
VKTX icon

Migdal Insurance & Financial Holdings’s Viking Therapeutics VKTX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,200
Closed -$6K – 699
2021
Q4 		$6K Sell
1,200
-724
-38% -$4.06K ﹤0.01% 641
2021
Q3 		$12K Buy
+1,924
New +$11.9K ﹤0.01% 586

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Migdal Insurance & Financial Holdings's VKTX Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Viking Therapeutics (VKTX) in Q1 2022, closing a stake of 1,200 shares — an estimated $6K sold.

Migdal Insurance & Financial Holdings first reported a position in VKTX in Q3 2021 and held it in 2 quarters. The position peaked at $12K in Q3 2021. 140 funds tracked by Wall St. Rank hold VKTX as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Viking Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 1,200 Viking Therapeutics shares in Q1 2022, an estimated $6K.
  • Migdal Insurance & Financial Holdings first reported a position in Viking Therapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Viking Therapeutics position peaked at $12K in Q3 2021.
  • 140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.